Cholinesterase inhibitors effects in patients with Lewy's bodies associated disease

Authors

  • Nilton Custodio Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica Internacional. Lima, Perú.
  • Rosa Montesinos Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica Internacional. Lima, Perú.
  • Liliana Bendezú Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica Internacional. Lima, Perú.
  • Patricia Cortijo Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica Internacional. Lima, Perú.
  • Hernando Torres Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica Internacional. Lima, Perú.
  • Juan Escobar Unidad de Diagnóstico de Deterioro Cognitivo y Prevención de Demencia, Clínica Internacional. Lima, Perú.

DOI:

https://doi.org/10.15381/anales.v69i3.1133

Keywords:

Parkinson disease, Lewy body disease, cholinesterase inhibitors, dementia, therapy.

Abstract

Objectives: To analyze the effects of cholinesterase inhibitors (CHEIs) prescribed for treatment of dementia with Lewy bodies (DLB) and dementia associated with Parkinson’s disease (PDD). Design: Open essay study. Setting: Neurology Service, Hospital Militar Central, and Cognitive Deterioration Diagnosis Unit and Dementia Prevention, Clinica Internacional. Participants: Patients with dementia associated to Lewy bodies and dementia associated with Parkinson’s disease. Interventions: Outcome measures included the Mini-Mental State Examination (MMSE), the Alzheimer Disease Assessment Scale cognitive subscale (ADAS-cog), Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC), Alzheimer’s Disease Cooperative Study-Activities of Daily Living Inventory (ADCS-ADL), Neuro-Psychiatry Inventory (NPI), Ten Point Clock-Drawing Test (CDT) and Unified Parkinson´s Disease Rating Scale-motor subscale (UPDRS-part III). Main outcome measures: Patients’ cognitive symptoms, global function and daily life activities. Results: Seventeen patients were treated with rivastigmine, nine with galantamine and seven with donepezil. At six months, rivastigmine-treated patients improved by 1,39 points from baseline on the ADAS-cog, while donepezil and galantamine treated patients showed ‘no change’ (changes of <0,2 points). On the ADCS-ADL, patients treated with rivastigmine, donepezil and galantamine showed decreases of 0,41, 0,68 and 0,86 points, respectively. On the MMSE, donepezil and rivastigmine-treated patients showed ‘no change’ and galantamine-treated patients showed a mean decrease of 1,19 points. The difference with regard to the incidence of parkinsonian symptoms as adverse events was not reflected in significant differences in UPDRS motor scores between the three groups. Side effects were similar in the three treatment groups. Conclusions: Cholinesterase inhibitors may be of benefit for cognitive impairments with impact on global function and activities of daily living in patients with dementia with Lewy bodies and dementia associated with Parkinson’s disease.

Downloads

Published

2008-09-15

Issue

Vol. 69 No. 3 (2008)

Section

Trabajos originales

License

Copyright (c) 2008 Nilton Custodio, Rosa Montesinos, Liliana Bendezú, Patricia Cortijo, Hernando Torres, Juan Escobar

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Those authors who have publications with this magazine accept the following terms:

  1. Authors will retain their copyrights and guarantee the journal the right of first publication of their work, which will be simultaneously subject to Creative Commons Attribution License that allows third parties to share the work as long as its author and its first publication this magazine are indicated.
  2. Authors may adopt other non-exclusive licensing agreements for the distribution of the version of the published work (eg, deposit it in an institutional electronic file or publish it in a monographic volume) provided that the initial publication in this magazine is indicated.
  3. Authors are allowed and recommended to disseminate their work over the Internet (eg: in institutional telematic archives or on their website) before and during the submission process, which It can produce interesting exchanges and increase quotes from the published work. (See El efecto del acceso abierto ).

How to Cite

1.
Custodio N, Montesinos R, Bendezú L, Cortijo P, Torres H, Escobar J. Cholinesterase inhibitors effects in patients with Lewy’s bodies associated disease. An Fac med [Internet]. 2008 Sep. 15 [cited 2024 Jul. 18];69(3):157-63. Available from: https://revistasinvestigacion.unmsm.edu.pe/index.php/anales/article/view/1133